| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 53,902 | 27,811 |
| Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents | 30,434 | 11,411 |
| Cash and cash equivalents at beginning of period | 13,986 | - |
| Cash and cash equivalents at end of period | 44,420 | - |
SELLAS Life Sciences Group, Inc. (SLS)
SELLAS Life Sciences Group, Inc. (SLS)